Oruka Therapeutics Q4 2022 Earnings Report $19.01 -0.97 (-4.85%) (As of 05:16 PM ET) Earnings HistoryForecast Oruka Therapeutics EPS ResultsActual EPS-$11.52Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOruka Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOruka Therapeutics Announcement DetailsQuarterQ4 2022Date2/24/2023TimeN/AConference Call ResourcesORKA Earnings History TSLA *BANG* incoming (bullet in the chamber rn) (Ad)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…Click here to review Tim’s special Holiday offer before it’s too late. Oruka Therapeutics Earnings HeadlinesHead to Head Survey: BG Medicine (OTCMKTS:BGMD) and Oruka Therapeutics (NASDAQ:ORKA)December 27 at 2:54 AM | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)December 25 at 1:47 PM | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 27, 2024 | Crypto Swap Profits (Ad)Oruka Therapeutics' (ORKA) "Buy" Rating Reiterated at HC WainwrightDecember 23, 2024 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Oruka Therapeutics (ORKA) and Adicet Bio (ACET)December 20, 2024 | markets.businessinsider.comOruka Therapeutics’s ORKA-001: Promising Psoriasis Treatment Drives Buy Rating with 12-Month Price Target of $45December 20, 2024 | markets.businessinsider.comSee More Oruka Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email. Email Address About Oruka TherapeuticsARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.View Oruka Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
